Their use in cardiovascular disease beyond these conditions has not yet been explored in human trials, although evidence suggests the involvement of PDE4 in disease states such as vascular diseases (atherosclerosis, restenosis, and cardiac hypertrophy, among others), whereby selective inhibitor of PDE4 could be beneficial [100]. Here, PDE4A is linked to cardiac hypertrophy.